X

The Lancet Oncology

The Lancet Oncology
Enasidenib Plus Azacitidine versus Azacitidine Alone in Patients With Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukaemia (AG221-AML-005)

This study evaluated the safety and activity of enasidenib plus azacitidine vs azacitidine alone in patients with newly diagnosed, mutant-IDH2 AML ineligible for intensive chemotherapy.

The Lancet Oncology
10/18/2021
Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone Alone in Newly Diagnosed Multiple Myeloma

A significant improvement in progression-free survival was observed with daratumumab plus lenalidomide and dexamethasone vs lenalidomide and dexamethasone alone...

The Lancet Oncology
10/13/2021
Apalutamide plus Abiraterone Acetate and Prednisone versus Placebo Plus Abiraterone and Prednisone in Metastatic, Castration-Resistant Prostate Cancer

Scientists investigate the combination treatment using apalutamide plus abiraterone acetate, each of which suppresses the androgen signalling axis in a different way, versus standard care in mCRPC.

The Lancet Oncology
09/30/2021
Lenvatinib With Etoposide Plus Ifosfamide in Patients With R/R Osteosarcoma

Investigators determine the recommended phase 2 dose and antitumour activity of lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma.

The Lancet Oncology
09/01/2021
Neural Stem Cell Delivery of an Oncolytic Adenovirus in Newly Diagnosed Malignant Glioma

Study investigators examine the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells, in patients with newly diagnosed high-grade glioma.

The Lancet Oncology
06/29/2021
Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Study investigators aim to evaluate the antitumour activity and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL.

The Lancet Oncology
06/01/2021
Avelumab Alone or in Combination With Chemotherapy versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Study investigators report results of avelumab alone or avelumab plus PLD compared with PLD alone in patients with platinum-resistant or platinum-refractory ovarian cancer.

The Lancet Oncology
06/15/2021
Chemotherapy De-escalation Using an 18F-FDG-PET-based Pathological Response-Adapted Strategy in Patients With HER2+ Early Breast Cancer

Study investigators assess early metabolic responses to neoadjuvant trastuzumab and pertuzumab using 18F-fluorodeoxyglucose and the possibility of chemotherapy de-escalation using...

The Lancet Oncology
05/18/2021
Pralsetinib for RET Fusion-Positive Non-Small-Cell Lung Cancer

Study investigators assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC.

The Lancet Oncology
06/09/2021
Patient-Reported Outcomes With Atezolizumab Plus Bevacizumab versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma

Study investigators evaluate patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in the IMbrave150 trial...

The Lancet Oncology
05/27/2021
Subscribe to The Lancet Oncology

source list reference

rgb(171, 222, 222)
#7d60d9
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
#352625
#4d4537
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
#d2093c
#8e3f1c
rgb(242, 0, 137)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(80, 147, 199)
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
#89f67c
#49a21d
rgb (132, 101, 173)
#2c990a
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
#a60538
rgb(2, 230, 230)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834